Siemens’ PETNET Solutions has announced a three-year agreement with The US Oncology Network to supply its entire portfolio of Food and Drug Administration (FDA)-approved PET radiopharmaceutical agents at each of PETNET Solutions’ current Good Manufacturing Practices (cGMP)-certified locations throughout the United States.

Definiens AG, a healthcare company that advances personalized medicine through image analysis and digital pathology solutions, and Advanced Cell Diagnostics (ACD) of Hayward California, a leader in molecular pathology, announced recently the commercial launch of RNAscope® SpotStudio™, a custom-designed image analysis software application for ACD's RNAscope®Assays to detect and quantify RNA biomarkers.

Siemens Healthcare has announced that the FDA has granted 510(k) clearance for Symbia Intevo—the world’s first xSPECT system, which combines the high sensitivity of single-photon emission computed tomography (SPECT) with the high specificity of CT.

Healthcare system selects UltraSPECT nuclear medicine software for lowering dose and reducing exam time.

Researchers are forever seeking to outsmart therapy-resistant cancers. "No Through Road," a feature published Aug. 5 in Cancer Today, a publication of the American Association for Cancer Research, highlights just this quest.

Siemens Healthcare has launched its new Biograph mCT Flow – a groundbreaking PET-CT system. For the first time ever the system overcomes the limitations of conventional bed-based PET-CT with FlowMotion, an innovative new technology that moves the patient smoothly through the system’s gantry, while continuously acquiring PET data.

Navidea Biopharmaceuticals announces award of a Small Business Innovation Research (SBIR) grant from the National Institute On Aging (NIA) of the National Institutes of Health (NIH) in connection with the Company's Phase 3 clinical program for its NAV4694 beta-amyloid imaging agent as an aid in the differential diagnosis of Alzheimer’s disease.

Navidea has signed an agreement with Siemens’ PETNET Solutions that grants PETNET Solutions the right to manufacture Navidea’s Fluorine-18 labeled NAV4694, an investigational beta-amyloid PET imaging agent, which is currently being evaluated in Phase 2 and 3 clinical trials evaluating subjects with signs or symptoms of cognitive impairment such as Mild Cognitive Impairment and Alzheimer’s disease.